Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | HTR2C | P28335 | 3/20 | 0.64 |
| ▸ | HTR1D | P28221 | 9/20 | 0.61 |
| ▸ | HTR7 | P34969 | 5/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252922 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR1DHTR7EGFR | |
| SCHEMBL7253554 | 0.91 | HTR2A (0.54) | HTR2AHTR2CHTR1DHTR7EGFR | |
| SCHEMBL20540198 | 0.87 | HTR2C (0.61) | HTR2AHTR2CHTR1DHTR7EGFR | |
| SCHEMBL7256513 | 0.84 | HTR7 (0.51) | HTR2AHTR2CHTR1DHTR7HTR6 | |
| SCHEMBL18239699 | 0.81 | HTR7 (0.57) | HTR2AHTR2CHTR1DHTR7HTR6 | |
| SCHEMBL23956080 | 0.81 | HTR2C (0.69) | HTR2AHTR2CHTR1DHTR7HTR6 | |
| SCHEMBL1122347 | 0.81 | HTR2C (0.64) | HTR2AHTR2CHTR1DHTR6NOS3 | |
| SCHEMBL20614497 | 0.78 | HTR1D (0.62) | HTR2AHTR2CHTR1DHTR7HTR6 | |
| SCHEMBL16741930 | 0.78 | EGFR (0.53) | HTR2AHTR2CHTR7EGFRNOS3 | |
| SCHEMBL23927832 | 0.78 | HTR2A (1.00) | HTR2AHTR2CHTR1DHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698529-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20240360139-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. | 2024-10-31 | — | — | US | disclosed |
| WO-2024220173-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360139-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | ROCK2, ROCK1, MYLK3 | HTR2A 1461/4885HTR2C 1544/4885HTR1D 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.